222 related articles for article (PubMed ID: 10226833)
1. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.
Miyanaga N; Akaza H; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Int J Urol; 1999 Apr; 6(4):173-7. PubMed ID: 10226833
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma.
Lee MY; Tsou MH; Cheng MH; Chang DS; Yang AL; Ko JS
World J Urol; 2000 Dec; 18(6):401-5. PubMed ID: 11204258
[TBL] [Abstract][Full Text] [Related]
4. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
5. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
6. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
[TBL] [Abstract][Full Text] [Related]
7. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
Chahal R; Darshane A; Browning AJ; Sundaram SK
Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer.
Miyanaga N; Akaza H; Ishikawa S; Ohtani M; Noguchi R; Kawai K; Koiso K; Kobayashi M; Koyama A; Takahashi T
Eur Urol; 1997; 31(2):163-8. PubMed ID: 9076459
[TBL] [Abstract][Full Text] [Related]
11. Detection of bladder cancer using a point-of-care proteomic assay.
Grossman HB; Messing E; Soloway M; Tomera K; Katz G; Berger Y; Shen Y
JAMA; 2005 Feb; 293(7):810-6. PubMed ID: 15713770
[TBL] [Abstract][Full Text] [Related]
12. Screening and monitoring for bladder cancer: refining the use of NMP22.
Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of urine NMP22 point-of-care test for the screening of bladder cancer].
Ihm CH; Kim JM; Sohn YH
Korean J Lab Med; 2007 Apr; 27(2):106-10. PubMed ID: 18094560
[TBL] [Abstract][Full Text] [Related]
15. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
16. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
17. [Novel NMP22 quick qualitative analysis (BladderChek NMP22) for the diagnosis of urothelial tumor].
Minagawa T; Nishizawa S; Kamigaito T; Okaneya T
Nihon Hinyokika Gakkai Zasshi; 2006 Jan; 97(1):20-6. PubMed ID: 16485550
[TBL] [Abstract][Full Text] [Related]
18. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
Gonzalo Rodríguez V; Sanz Justo L; de Miguel Santamaría I; Martínez de Iturrate J; Fernández del Busto E
Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]